Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Pathology

• Publication date

  2014-08-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/jclinpath-2014-202347PMID 25118293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathology And Genetics Of Tumours Of The Lung Pleura Thymus And Heart

  2016cited by this paper
• Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

  2014cited by this paper
• Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas.

  2013cited by this paper
• The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer

  2013cited by this paper
• Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

  2013cited by this paper
• Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

  2013cited by this paper
• Molecular biology of lung cancer.

  2013cited by this paper
• Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

  2013cited by this paper
• Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

  2013cited by this paper
• Inhibition of insulin-like growth factor receptor: end of a targeted therapy?

  2012cited by this paper
• Insulin-like growth factor receptor inhibitors: baby or the bathwater?

  2012cited by this paper
• Clinical significance of IGF1R expression in non-small-cell lung cancer.

  2012cited by this paper
• Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

  2010cited by this paper
• Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer

  2010cited by this paper
• Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

  2010cited by this paper
• Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

  2009cited by this paper
• Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue.

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• Tissue Microarray Validation: A Methodologic Study with Special Reference to Lung Cancer

  2009cited by this paper
• High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

  2009cited by this paper
• High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

  2009cited by this paper
• Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

  2009cited by this paper
• Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis

  2008cited by this paper
• Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

  2008cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

  2002cited by this paper
• Molecular biology of lung cancer.

  2001cited by this paper
• Expression of insulin-like growth factor-1 receptor in human colorectal cancer.

  1999cited by this paper
• Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor.

  1993cited by this paper

• Targeting obesity-related dysfunction in hormonally driven cancers

  2021cites this paper
• Molecular Biology of Lung Cancer and Future Perspectives for Screening

  2019cites this paper
• Insulin-like growth factor-1 receptor expression in pediatric tumors: a comparative immunohistochemical study

  2018cites this paper
• The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

  2017cites this paper
• Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival

  2017cites this paper
• Insulin-like growth factor (IGF) axis in cancerogenesis.

  2017cites this paper
• Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies

  2017cites this paper
• Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

  2017cites this paper
• Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target

  2017cites this paper
• EGR 1 , EGFR and IGF 1 R protein expressions in non-small cell lung cancer and their clinical significances

  2016cites this paper
• Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer.

  2016cites this paper
• Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer.

  2016cites this paper
• Lung Cancer Staging and Prognosis.

  2016cites this paper
• EGR1, EGFR and IGF1R protein expressions in non-small cell lung cancer and their clinical significances

  2016cites this paper
• Signalisation nucléaire de l'IGF-1R et résistance aux thérapies anti-EGFR dans les cancers du poumon

  2016cites this paper
• MicroRNA 30 a inhabits tumor invasiveness and metastasis by targeting IGF 1 R in non-small lung cancer

  2016cites this paper
• 5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.

  2015cites this paper
• MULTILEVEL DEREGULATION OF SURVIVAL MECHANISMS IN NPM-ALK+ T-CELL LYMPHOMA

  2015cites this paper
• A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer

  2015cites this paper